Stacking Up LMAT Against Its Peers – Is It Still a Buy?
Here is how LeMaitre Vascular (LMAT) stacks up against its peers in size, valuation, growth and margin.
- LMAT’s operating margin of 23.3% is high, but higher than most peers – though lower than IDXX (31.1%).
- LMAT’s revenue growth of 14.1% in the last 12 months is strong, outpacing MASI, EW, IDXX but lagging ATRC, UFPT.
- LMAT’s stock gained 13.8% over the past year and trades at a PE of 46.3, though peers like ATRC, MASI, EW, IDXX delivered stronger returns.
As a quick background, LeMaitre Vascular provides medical devices and implants for peripheral vascular disease, including fiberoptic angioscopes and carotid shunts for blood flow management during surgery.
| LMAT | ATRC | UFPT | MASI | EW | IDXX | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 2.2 | 1.7 | 1.7 | 7.9 | 47.8 | 51.5 |
| Revenue ($ Bil) | 0.2 | 0.5 | 0.6 | 1.8 | 5.7 | 4.0 |
| PE Ratio | 46.3 | -47.3 | 25.2 | -17.2 | 11.5 | 52.2 |
| LTM Revenue Growth | 14.1% | 16.3% | 41.0% | 8.0% | 9.1% | 6.7% |
| LTM Operating Margin | 23.3% | -6.8% | 16.6% | 6.5% | 27.9% | 31.1% |
| LTM FCF Margin | 22.3% | 1.7% | 12.3% | 7.3% | 10.2% | 19.2% |
| 12M Market Return | 13.8% | 52.7% | -33.3% | 19.7% | 17.3% | 29.5% |
Why does this matter? LMAT just went up 20.1% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell LMAT Stock to see if LeMaitre Vascular holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through LMAT Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| LMAT | 14.1% | 13.6% | 19.7% | 4.7% |
| ATRC | 16.3% | 16.5% | 20.8% | 20.4% |
| UFPT | 41.0% | 26.1% | 13.1% | 71.5% |
| MASI | 8.0% | 2.3% | 0.6% | 64.3% |
| EW | 9.1% | 8.6% | 12.2% | -14.7% |
| IDXX | 6.7% | 6.5% | 8.7% | 4.7% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| LMAT | 23.3% | 23.8% | 19.2% | 18.5% |
| ATRC | -6.8% | -8.6% | -6.7% | -12.9% |
| UFPT | 16.6% | 16.7% | 15.3% | 12.6% |
| MASI | 6.5% | 1.8% | 8.0% | 10.3% |
| EW | 27.9% | 27.2% | 29.7% | 34.5% |
| IDXX | 31.1% | 29.0% | 30.0% | 26.7% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| LMAT | 46.3 | 47.0 | 41.9 | 49.0 |
| ATRC | -47.3 | -32.1 | -54.3 | -43.7 |
| UFPT | 25.2 | 31.8 | 29.2 | 21.3 |
| MASI | -17.2 | -28.9 | 75.9 | 55.3 |
| EW | 11.5 | 10.6 | 33.0 | 30.3 |
| IDXX | 52.2 | 38.4 | 54.6 | 50.2 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.